Early Hormone Therapy Cuts Heart Risk in Menopause

Up to 80% of women experience hot flashes and night sweats during menopause, symptoms tied to blood vessel changes that can persist for seven to ten years. These symptoms intensify as perimenopause progresses and reach their peak in early post-menopause, driving many women to pursue hormone replacement therapy (HRT). Research confirms HRT remains the most effective treatment for these symptoms, though concerns persist about its long-term health impact.

Heart disease risk declines with early HRT use

A 20-year analysis of health records from over 2,700 women in the Study of Women’s Health Across the Nation (SWAN) project found that participants without pre-existing heart disease benefited from HRT. Among the 750 women using HRT to manage symptoms, the risk of cardiovascular events, including heart attacks, strokes, and congestive heart failure, dropped by 22% compared to non-users.

The timing of HRT initiation played a decisive role. Women who began treatment within 10 years of menopause onset saw a 27% lower risk of cardiovascular disease. The study suggests early use may counteract age-related vascular decline, as plaque buildup and arterial stiffness worsen with advancing menopause. Researchers acknowledged the need for additional studies to clarify these effects.

Racial differences also emerged in the data. Black women who started HRT during perimenopause or early post-menopause experienced a 49% reduced risk of cardiovascular events. Given that Black women often endure more severe vasomotor symptoms, the results point to the necessity of customized HRT strategies for different demographic groups.

SWAN data simulate randomized trials to evaluate cardiovascular outcomes

Clinical trials conducted in the early 2000s raised concerns that hormone replacement therapy could increase a woman’s risk of heart disease, stroke and breast cancer.

The SWAN project enabled researchers to mimic a series of randomized clinical trials. “It allowed us to study clinically meaningful cardiovascular events in a population and for a length of treatment that has been challenging to study prospectively,” a senior investigator explained. Samar El Khoudary, a senior investigator on the study, told TheDoctor.

Breast cancer risk increases with prolonged HRT

While early HRT appears to lower cardiovascular risk, the study reinforced a well-documented risk: extended use raises breast cancer likelihood. The findings align with existing guidelines, which recommend HRT for women under 60 within 10 years of menopause, prescribed for the shortest effective period. Personal medical history remains a key consideration for individual decisions.

The study’s observational design prevents definitive conclusions about causation. Samar El Khoudary, the lead investigator and chair of the epidemiology department at Virginia Commonwealth University, stressed that the findings should be interpreted carefully because the study was observational and it cannot determine whether MHT caused the observed differences. The research was published in JAMA Internal Medicine, accompanied by an editorial.